Enveric Biosciences Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
6
- Stock Symbol
-
ENVB
- Investments
-
10
- Share Price
-
$1.52
- (As of Thursday Closing)
Enveric Biosciences General Information
Description
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Contact Information
Website
www.enveric.comCorporate Office
- 245 First Street, Riverview II
- 18th Floor
- Cambridge, MA 02142
- United States
Corporate Office
- 245 First Street, Riverview II
- 18th Floor
- Cambridge, MA 02142
- United States
Enveric Biosciences Timeline
Enveric Biosciences Stock Performance
As of 12-Nov-2026, Enveric Biosciences’s stock price is $1.52. Its current market cap is $6.8M with 4.48M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.52 | $1.49 | $1.17 - $13.25 | $6.8M | 4.48M | 72.3K | -$13.01 |
Enveric Biosciences Financials Summary
As of 30-Jun-2026, Enveric Biosciences has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 651 | (43) | 543 | (1,249) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (8,575) | (8,571) | (9,229) | (16,858) |
| Net Income | (8,729) | (8,772) | (9,575) | (17,311) |
| Total Assets | 8,944 | 5,096 | 3,083 | 4,300 |
| Total Debt | 0 | 0 | 0 | 0 |
Enveric Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Enveric Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Enveric Biosciences Patents
Enveric Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12059393-B2 | Compositions for topical treatment of radiation dermatitis | Active | 11-Feb-2022 | ||
| US-20230255900-A1 | Compositions for topical treatment of radiation dermatitis | Active | 11-Feb-2022 | ||
| US-11660348-B1 | Cannabinoid conjugate molecules | Active | 01-Feb-2022 | ||
| US-11883499-B2 | Cannabinoid conjugate molecules | Active | 01-Feb-2022 | ||
| US-20230293700-A1 | Cannabinoid conjugate molecules | Active | 01-Feb-2022 | A61K47/55 |
Enveric Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Enveric Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Enveric Biosciences Acquisitions (10)
Enveric Biosciences’s most recent deal was a Merger/Acquisition with MagicMed Industries for . The deal was made on 16-Sep-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MagicMed Industries | 16-Sep-2021 | Merger/Acquisition | Drug Discovery | ||
| Jay Pharma | 30-Dec-2020 | Merger/Acquisition | Drug Discovery | ||
| ATCG Solutions | 10-Mar-2017 | Merger/Acquisition | IT Consulting and Outsourcing | ||
| Bigtech Software | 23-Sep-2016 | Merger/Acquisition | Business/Productivity Software | ||
| DC&M Partners | 01-Aug-2016 | Merger/Acquisition | Consulting Services (B2B) |
Enveric Biosciences ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Enveric Biosciences Exits (1)
Enveric Biosciences’s most recent exit was on 25-Jul-2016 from Ameri100 Virtuoso. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Ameri100 Virtuoso | 25-Jul-2016 | Completed |
|
Enveric Biosciences FAQs
-
When was Enveric Biosciences founded?
Enveric Biosciences was founded in 1994.
-
Where is Enveric Biosciences headquartered?
Enveric Biosciences is headquartered in Cambridge, MA.
-
What is the size of Enveric Biosciences?
Enveric Biosciences has 6 total employees.
-
What industry is Enveric Biosciences in?
Enveric Biosciences’s primary industry is Drug Discovery.
-
Is Enveric Biosciences a private or public company?
Enveric Biosciences is a Public company.
-
What is Enveric Biosciences’s stock symbol?
The ticker symbol for Enveric Biosciences is ENVB.
-
What is the current stock price of Enveric Biosciences?
As of 12-Nov-2026 the stock price of Enveric Biosciences is $1.52.
-
What is the current market cap of Enveric Biosciences?
The current market capitalization of Enveric Biosciences is $6.8M.
-
What is Enveric Biosciences’s annual earnings per share (EPS)?
Enveric Biosciences’s EPS for 12 months was -$13.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
